When a patient with cancer is told the devastating news that their disease has spread, or metastasized, to a new part of their body, it has most often moved to their lungs. The branching blood vessels that allow oxygen to diffuse from the lungs’ air sacs into red blood cells are so tiny that a rogue cancer cell circulating in the bloodstream can easily get stuck there and take up residence, eventually growing into a secondary tumor. Once established, metastatic tumors unleash a campaign of chemical cues that thwart the body’s defenses, hampering efforts to induce an immune response. There are no treatments approved for lung metastasis, which is the leading cause of death from metastatic disease.
That grim prognosis may soon be less grim thanks to a new technique developed by researchers at the Harvard John A. Paulson School for Engineering and Applied Sciences (SEAS) and Harvard’s Wyss Institute for Biologically Inspired Engineering. Rather than viewing lung metastasis as unfortunate fallout from a primary tumor elsewhere, the team focused on treating the metastasis itself by delivering immune-cell-attracting chemicals into lung cancers via red blood cells. Not only did this approach halt lung tumor growth in mice with metastatic breast cancer, it also acted as a vaccine and protected the animals against future cancer recurrences.
seas.harvard.edu/news/2020/...
Nature Biomedical Engineering. Research Paper:
This wee demon has returned
Regular seasonal flare-ups
New drug approved in Europe for uncontrolled COPD. 
Mycophenolate instead of Perfinedine or Nintenanib? 
